Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms VISNU-2
- 31 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2018.
- 10 Jun 2017 Biomarkers information updated